Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 33Active not recruiting 16Recruiting 4Terminated 3

Sponsor Class

OTHER 18INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1Dermatologic 1

Conditions

Prostatic Neoplasms 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × tremelimumab × Clear all
NCT02616185 2023-11-02

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

Pfizer

Phase 1 Terminated
91 enrolled 51 charts
Genitourinary

Prostatic Neoplasms

NCT02205333 2017-06-28

MEDI6469

MedImmune LLC

Phase 1/2 Terminated
48 enrolled 28 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT00585000 2012-06-06

A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma

AstraZeneca

Phase 1 Terminated
49 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡